CNCatherine Noguès

Catherine Noguès

*This is an algorithmically generated author record based on publicly available information.

Catherine Noguès has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Que penser de l’hormonoprévention du cancer du sein chez les femmes porteuses d’une mutation délétère BRCA1/BRCA2 ?

    by Claire Sénéchal, Fabien Reyal, Nasrine Callet, Pascale This, Catherine Noguès, Dominique Stoppa-Lyonnet, Emmanuelle Fourme


  • Open Access

    GENESIS: a French national resource to study the missing heritability of breast cancer

    by Olga M. Sinilnikova, Marie-Gabrielle Dondon, Séverine Eon-Marchais, Francesca Damiola, Laure Barjhoux, Morgane Marcou, Carole Verny-Pierre, Valérie Sornin, Lucie Toulemonde, Juana Beauvallet, et al.

    Less than 20 % of familial breast cancer patients who undergo genetic testing for BRCA1 and BRCA2 carry a pathogenic mutation in one of these two genes. The GENESIS (GENE SISter) study was designed to identify new breast cancer susceptibility genes in women attending cancer genetics clinics and with no BRCA1/2 mutation. The study involved the French national network of family cancer clinics. It was based on enrichment in genetic factors of the recruited population through case selection relying on familial criteria, but also on the consideration of environmental factors and endophenotypes like mammary density or tumor characteristics to assess potential genetic heterogeneity. One of the initial aims of GENESIS was to recruit affected sibpairs. Siblings were eligible when index cases and at least one affected sister were diagnosed with infiltrating mammary or ductal adenocarcinoma, with no BRCA1/2 mutation. In addition, unrelated controls and unaffected sisters were recruited. The enrolment of patients, their relatives and their controls, the collection of the clinical, epidemiological, familial and biological data were centralized by a coordinating center. Inclusion of participants started in February 2007 and ended in December 2013. A total of 1721 index cases, 826 affected sisters, 599 unaffected sisters and 1419 controls were included. 98 % of participants completed the epidemiological questionnaire, 97 % provided a blood sample, and 76 % were able to provide mammograms. Index cases were on average 59 years old at inclusion, were born in 1950, and were 49.7 years of age at breast cancer diagnosis. The mean age at diagnosis of affected sisters was slightly higher (51.4 years). The representativeness of the control group was verified. The size of the study, the availability of biological specimens and the clinical data collection together with the detailed and complete epidemiological questionnaire make this a unique national resource for investigation of the missing heritability of breast cancer, by taking into account environmental and life style factors and stratifying data on endophenotypes to decrease genetic heterogeneity.


  • Les défis de l’oncogénétique et ses applications médicales : nouvelles problématiques psycho-oncologiques ? Le modèle des prédispositions génétiques au cancer du sein et de l’ovaire

    by C. Noguès

    L’augmentation des connaissances sur les facteurs de prédisposition génétique au cancer permet de donner des éléments de réponse aux interrogations d’un nombre croissant de familles et de leurs médecins, et également de mettre en place la prise en charge médicale adaptée. Un résultat de prédisposition génétique a néanmoins des implications profondes pour les familles malmenées par les cancers. Le modèle de la prédisposition au cancer du sein (CS) et de l’ovaire (CO) est emblématique de certaines problématiques ou avancées en oncogénétique (OG) et de leur impact pour les patients et les soignants; suivi au long cours des femmes à risque, questionnements autour du projet parental, information à la parentèle, enjeux des consultations théranostiques, retombées des analyses de panel de gènes. La capacité du dispositif actuel à répondre aux demandes et à s’adapter aux nouveaux enjeux est réelle mais reste un challenge. La qualité des informations données et la préservation d’un accompagnement spécifique médical et psycho-oncologique paraissent essentielles.


    • 1 March 2004
      • Vol. 91  (3) , 219-37

    [Identification and management of hereditary predisposition to cancer of the breast and the ovary (update 2004)].

    by François Eisinger, Brigitte Bressac, Damienne Castaigne, Pierre-Henri Cottu, Jacques Lansac, Jean-Pierre Lefranc, Anne Lesur, Catherine Noguès, Janine Pierret, Séverine Puy-Pernias, et al.

    Since the last recommendations, up to 2,500 new references had been published on that topic. On the behalf of the health Minister, the Ad Hoc Committee consisted of 13 experts carried out a first version revisited by five additional experts who critically analyzed the first version of the report. Breast and ovarian cancer seem to be associated with fewer deleterious mutation of BRCA12 and BRCA2 than previously thought. The screening of ovarian cancer is still not an attractive option while in contrast MRI may be soon for these young women with dense breast, the recommended option for breast cancer screening. The effectiveness of prophylactic surgeries is now well established. French position is to favor such surgeries with regard to a quality of life in line with the expected benefit, and providing precise and standardized process described in the recommendation. Due to methodological flaws, the low power and a short follow-up of the surveys, this statement cannot however aspire to a high stability.


    • 1 February 2003
      • Vol. 12  (2) , 90-5

    BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations.

    by Sophie M Ginolhac, Sophie Gad, Marilys Corbex, Brigitte Bressac-De-Paillerets, Agnès Chompret, Yves-Jean Bignon, Jean-Philippe Peyrat, Joelle Fournier, Christine Lasset, Sophie Giraud, et al.

    Strong inter- and intrafamilial variation of penetrance of breast and ovarian cancer is observed in BRCA1 mutation carriers. The wild-type copy of the BRCA1 gene is a plausible candidate as a cancer risk modifier given that the residual function corresponding to the intact BRCA1 allele may influence the process of tumor formation in BRCA1 carriers. Indeed, growing evidence is now becoming available on impaired reparation of double-strand DNA breaks in cells heterozygous for BRCA1 mutations, implying an enhanced mutability of BRCA1(+/-) cells. To determine whether certain variant forms of the wild-type BRCA1 allele are implicated in variation of the BRCA1-related cancer risk, their effect was studied in a panel of 591 women with BRCA1 germ-line mutations. We found that BRCA1 carriers with the wild-type BRCA1 copy bearing a common Gly1038 variant were at increased risk of ovarian cancer (hazards ratio, 1.50; 95% confidence interval, 1.03-2.19). The results of our study imply that a quite significant proportion of the interindividual variability in ovarian cancer penetrance in BRCA1 carriers may be explained by a common BRCA1 Gly1038 wild-type allele, given its high frequency (0.27).